Company Profile

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Companyâ€™s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.

Employees

Sector

Entertainment Production

More about the company

09-02	XOMA Royalty Corporation Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-14	Ligand Pharmaceuticals Incorporated completed the acquisition of XOMA Royalty Corporation from a group of shareholders.	CI
07-14	Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase	MT
07-14	XOMA Royalty Corp Announces Management Changes	CI
07-14	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from S&P TMI Index	CI
07-14	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from S&P Global BMI Index	CI
07-14	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from NASDAQ Composite Index	CI
07-13	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell 3000 Value Benchmark	CI
07-13	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Small Cap Comp Value Benchmark	CI
07-13	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Small Cap Comp Growth Benchmark	CI
07-13	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Microcap Value Benchmark Index	CI
07-13	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell Microcap Growth Benchmark Index	CI
07-13	XOMA Royalty Corporation(NasdaqGM:XOMA) dropped from Russell 3000E Value Benchmark	CI

04-30	HC Wainwright Downgrades XOMA Royalty to Neutral From Buy, Adjusts Price Target to $39 From $97	MT
11-12	Biotech royalty aggregator XOMA reports Q3 net income of $14.1 mln	RE
17/09/25	XOMA Royalty announces closing of tender offer for HilleVax	RE
17/04/25	Benchmark Initiates XOMA Royalty at Buy With $35 Price Target	MT
29/04/24	Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target	MT

07-14	XOMA Royalty : Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date	PU
07-14	XOMA Royalty Announces Closing of Its Acquisition by Ligand	AQ
06-12	XOMA Royalty : Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator	PU
06-12	XOMA Royalty Corporation Declares Quarterly Preferred Stock Dividend and Announces Redemption of Its Perpetual Preferred Stock and CVR Dividend Record Date	AQ
04-28	XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA	BU

28/10/23	Obseva: Organon rétrocède la licence pour Ebopiprant, paiement d'étape éteint
28/10/23	Obseva: Organon gibt Lizenz für Ebopiprant zurück - Meilensteinanspruch erlischt
15/03/23	Kuros: le déploiement commercial du Magnetos a creusé le déficit en 2022
24/02/23	Obseva réduit la voilure autour de ses actifs restants
19/12/22	Obseva: la demande de retrait de sursis concordataire est acceptée

Manager	Title	Age	Since
Owen Hughes CEO	Chief Executive Officer	51	01/01/2023
Jeffrey Trigilio DFI	Director of Finance/CFO	42	12/01/2026
Bradley Sitko CIO	Chief Investment Officer	45	03/01/2023

XOMA Royalty Corporation Stock NYSE

Stocks

XOMAP

US98419J3059

Entertainment Production

Chart: XOMA Royalty Corporation

Latest news: XOMA Royalty Corporation

Last Transcript: XOMA Royalty Corporation

Analysts' recommendations: XOMA Royalty Corporation

Press Releases: XOMA Royalty Corporation

News in other languages: XOMA Royalty Corporation

Quotes and Performance

Managers and Directors: XOMA Royalty Corporation

Copyright Management

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XOMA ROYALTY CORPORATION	+0.04%	+0.08%	-	-	710M
LIVE NATION ENTERTAINMENT, INC.	+1.89%	-1.56%	+27.12%	+105.75%	41.58B
SKYDANCE CORPORATION	-0.68%	-3.81%	-51.79%	-32.75%	40.54B
UNIVERSAL MUSIC GROUP N.V.	+0.15%	-2.87%	-24.31%	-27.19%	34.44B
WARNER MUSIC GROUP CORP.	-0.42%	-2.47%	+4.36%	-2.38%	16.66B
TKO GROUP HOLDINGS, INC.	+0.24%	+6.42%	+11.19%	+151.35%	14.43B
BOLLORÉ SE	+0.33%	-3.80%	-22.79%	-29.59%	11.55B
MANGO EXCELLENT MEDIA CO., LTD.	-0.70%	+27.88%	+30.94%	+23.65%	9.95B
TOHO CO., LTD.	-2.60%	+3.44%	-6.53%	+70.81%	9.38B
MSG KNICKERBOCKERS CORP.	+0.57%	-2.11%	+45.06%	+87.60%	7.63B
Average	-0.12%	+3.15%	+1.47%	+38.58%	21B
Weighted average by Cap.	+0.15%	+1.59%	-6.70%	+29.57%